PDL BIOPHARMA INC's ticker is PDLI and the CUSIP is 69329Y104. A total of 193 filers reported holding PDL BIOPHARMA INC in Q4 2016. The put-call ratio across all filers is 0.18 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $22,000 | -52.2% | 10,301 | -24.9% | 0.00% | – |
| Q3 2016 | $46,000 | -77.7% | 13,710 | -79.1% | 0.00% | -100.0% |
| Q2 2016 | $206,000 | -14.2% | 65,550 | -9.2% | 0.00% | 0.0% |
| Q1 2016 | $240,000 | -4.0% | 72,206 | +2.3% | 0.00% | 0.0% |
| Q4 2015 | $250,000 | -38.1% | 70,583 | -12.1% | 0.00% | -50.0% |
| Q3 2015 | $404,000 | -13.3% | 80,329 | +10.9% | 0.00% | -20.0% |
| Q2 2015 | $466,000 | +7.1% | 72,466 | +17.1% | 0.01% | 0.0% |
| Q1 2015 | $435,000 | +5.1% | 61,904 | +15.4% | 0.01% | 0.0% |
| Q4 2014 | $414,000 | -2.4% | 53,635 | -5.6% | 0.01% | 0.0% |
| Q3 2014 | $424,000 | -37.6% | 56,805 | -19.1% | 0.01% | -37.5% |
| Q2 2014 | $680,000 | +31.0% | 70,204 | +12.4% | 0.01% | +14.3% |
| Q1 2014 | $519,000 | +47.9% | 62,448 | +50.1% | 0.01% | +40.0% |
| Q4 2013 | $351,000 | +161.9% | 41,605 | +146.7% | 0.01% | +150.0% |
| Q3 2013 | $134,000 | +7.2% | 16,864 | +3.9% | 0.00% | 0.0% |
| Q2 2013 | $125,000 | – | 16,230 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARMISTICE CAPITAL, LLC | 2,632,000 | $8,817,000 | 2.83% |
| AMERICAFIRST CAPITAL MANAGEMENT, LLC | 551,804 | $1,848,543,000 | 1.54% |
| Nine Chapters Capital Management LLC | 24,300 | $81,000 | 0.57% |
| GREAT POINT PARTNERS LLC | 645,000 | $2,161,000 | 0.55% |
| Virtus ETF Advisers LLC | 198,901 | $666,000 | 0.32% |
| GSA CAPITAL PARTNERS LLP | 1,521,224 | $5,096,000 | 0.27% |
| Amici Capital, LLC | 200,000 | $670,000 | 0.18% |
| Acrospire Investment Management LLC | 70,622 | $237,000 | 0.16% |
| RBF Capital, LLC | 273,976 | $918,000 | 0.16% |
| SECOR Capital Advisors, LP | 383,971 | $1,286,000 | 0.14% |